February 2023
-
02.17.2023 Vaccines Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 -
02.10.2023 Research Vaccines Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program
January 2023
-
01.30.2023 Leadership Medicines Partnerships Responsibility Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030 -
01.27.2023 Research Pfizer Responds to Research Claims -
01.27.2023 Covid-19 Medicines Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union -
01.17.2023 Investments Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena
December 2022
-
12.22.2022 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, Due To The Presence of Visible Glass Particulates -
12.20.2022 Medicines U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™ -
12.13.2022 Covid-19 Medicines Partnerships Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19 -
12.09.2022 Research Vaccines Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
November 2022
-
11.23.2022 Covid-19 Medicines Pfizer Signs Agreement to Provide the European Union with PAXLOVID™ -
11.16.2022 Covid-19 Research Vaccines Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection